Here’s how analysts see Ignyta, Inc. (NASDAQ:RXDX) after this past week.

June 14, 2018 - By Kurt Siggers

Ignyta, Inc. (NASDAQ:RXDX) Logo

Ignyta, Inc. (NASDAQ:RXDX) Ratings Coverage

Among 3 analysts covering Ignyta Inc (NASDAQ:RXDX), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Ignyta Inc had 3 analyst reports since December 22, 2017 according to SRatingsIntel. As per Tuesday, December 26, the company rating was downgraded by Ladenburg Thalmann. SunTrust downgraded the shares of RXDX in report on Tuesday, December 26 to “Hold” rating. The stock of Ignyta, Inc. (NASDAQ:RXDX) has “Hold” rating given on Friday, December 22 by Jefferies. Below is a list of Ignyta, Inc. (NASDAQ:RXDX) latest ratings and price target changes.

26/12/2017 Broker: SunTrust Rating: Hold Downgrade
26/12/2017 Broker: Ladenburg Thalmann Old Rating: Buy New Rating: Neutral Downgrade
22/12/2017 Broker: Jefferies Rating: Hold New Target: $27.0 Downgrade

It closed at $26.95 lastly. It is up 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Ignyta, Inc., a precision oncology biotechnology company, engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases. The company has market cap of $. The Company’s products pipeline includes entrectinib, a tyrosine kinase inhibitor directed to the tropomyosin receptor kinase family tyrosine kinase receptors, ROS1, and anaplastic lymphoma kinase proteins, which is in Phase II and two Phase I clinical studies in molecularly defined adult patient populations for the treatment of solid tumors, as well as in Phase I/Ib clinical study in pediatric patients with advanced solid tumor malignancies; RXDX-105, an orally bioavailable and vascular endothelial growth factor receptor, and small molecule tyrosine kinase inhibitor of RET-driven solid tumors; and RXDX-106, a pseudo-irreversible inhibitor, which is in late preclinical development. It currently has negative earnings.

Ignyta, Inc. (NASDAQ:RXDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.